Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Organisation › Details

Celyad S.A. (Euronext Brussels + Paris: CYAD, Nasdaq: CYAD)

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015. Celyad’s ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad’s American Depositary Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD. *


Period Start 2015-05-05 renamed
  Group Celyad (Group)
  Predecessor Cardio3 BioSciences S.A. (Euronext Brussels: CARD)
Products Industry C-Cure® cell therapy
  Industry 2 C-Cathez®
Persons Person Homsy, Christian (Cardio3 BioSciences 201305 CEO)
  Person 2 Petti, Filippo (Celyad 201809– before Wells Fargo Securities + William Blair + Webush Securities + OSI Pharmaceuticals)
Region Region Mont-Saint-Guibert
  Country Belgium
  Street 12 Rue Edouard Belin
  City 1435 Mont-Saint-Guibert
  Tel +32-10-394100
    Address record changed: 2018-07-24
Basic data Employees C: 51 to 100 (2015-12-31)
  Currency EUR
  Annual sales 8,523,000 (revenues, consolidated (2016) 2016-12-31)
  Profit -23,606,000 (2016-12-31)
  Cash 55,900,000 (2018-09-30)
    * Document for �About Section�: Celyad S.A.. (12/7/15). "Press Release: Celyad Announces the Appointment of Pierre Brynaert as Chief Human Resources Officer". Mont-Saint-Guibert.
Record changed: 2018-11-21


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Celyad (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top